New Review Sets Out Updated Treatment Path for Multiple Myeloma

The New England Journal of Medicine has posted a review of current multiple myeloma (a cancer of plasma cells in the bone marrow) treatment, written by Dr Tarek H. Mouhieddine and Dr Kenneth C. Anderson. The review covers the full treatment journey — from first diagnosis through to relapse — and reflects how clinical practice has changed over recent years.

According to the review, four-drug induction therapy (an initial intensive treatment phase combining four medicines) is now a standard starting point. The authors also describe how decisions around stem cell transplantation are being tailored more carefully to individual patients rather than applied as a blanket approach.

Maintenance therapy — lower-dose treatment given after the main course to keep the disease in check — is similarly described as needing to be matched to each patient’s profile. And in cases where the disease returns, the review highlights a shift towards using BCMA-directed immunotherapy (treatments that target a protein found on myeloma cells, called B-cell maturation antigen) at an earlier stage than was previously typical.

The review does not set out new research findings of its own. It is a clinical summary, drawing together existing evidence to guide doctors on current best practice.

Multiple myeloma is not among the most common cancers, but it is the second most common blood cancer in the UK, according to the NHS.

Anyone concerned about symptoms — which the NHS lists as bone pain, tiredness, frequent infections, and unusual bruising or bleeding — should speak to their GP in the first instance. NHS 111 is also available for non-emergency health queries.

Key information

• GP appointments: The first point of contact for anyone with concerns about symptoms linked to blood cancers
• NHS 111: Available 24 hours a day for non-emergency health guidance — call 111 or use the online service
• Emergencies: Call 999